NCT02189317View on ClinicalTrials.gov

Liposomal Bupivacaine for Pain Control Following Anterior Cruciate Ligament Reconstruction

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Anterior Cruciate Ligament Rupture
Interventions
DRUG

Exparel

For the treatment group a total of 40 cc consisting of 20 cc of 1.3% Exparel® and 20 cc of 0.5 % marcaine will be administered to the ACL harvest site, into the periosteum surrounding the distal tibial tunnel site, and in the proximity of the skin incisions. No infiltration of Exparel will be provided intra-articularly.

Trial Locations (1)

30324

Emory University Orthopaedic and Spine Center, Atlanta

All Listed Sponsors
lead

Emory University

OTHER

NCT02189317 - Liposomal Bupivacaine for Pain Control Following Anterior Cruciate Ligament Reconstruction | Biotech Hunter | Biotech Hunter